If this message does not display properly, please click here to launch your browser
| What Key Drug Attributes Will Emerging Therapies Need to Erode the Dominance of TNF-alpha Inhibitors in Moderate to Severe Psoriasis? — A Webinar from Decision Resources | |||
Based on our DecisionBase 2010 report entitled Psoriasis: Dermatologists Identify Remaining Opportunities as the Number of Highly Efficacious Biologics Continues to Grow, Decision Resources is offering an exclusive webinar entitled What Key Drug Attributes Will Emerging Therapies Need to Erode the Dominance of TNF-alpha Inhibitors in Moderate to Severe Psoriasis? Because this webinar will feature major report findings, it is ONLY available to purchasers of this report. Please contact us to learn how you can purchase this report and attend the webinar. In the moderate to severe psoriasis drug market, the launch of new therapies from existing and novel drug classes will fuel intense competition and increase dermatologists’ expectations regarding efficacy and longer-term safety. However, the safety and delivery shortcomings of current agents present opportunities for emerging therapies which offer clinical profiles that are at least similar to those of marketed biologics. The moderate to severe psoriasis market accounts for approximately 80 percent of total psoriasis sales although Decision Resources estimates that only a third of drug-treated patients fall into this category. Market dynamics in the moderate to severe psoriasis segment are expected to be especially intense over the next 10 years as the current sales leader, Amgen/Pfizer/Takeda’s Enbrel – a TNF-alpha inhibitor – will continue to lose share to its closest competitor from the same drug class, Abbott/Eisai’s Humira. Additionally, Enbrel is expected to lose share to the more-efficacious interleukin 12/23 inhibitor, Centocor Ortho Biotech/Janssen-Cilag’s Stelara as well as emerging biosimilar agents. This webinar, presented by Decision Resources Analyst Irene Koulinska, M.D., will answer the following questions:
Dr. Koulinska will conduct a live Q & A session after the presentation. Registration What Key Drug Attributes Will Emerging Therapies Need to Erode the Dominance of TNF-alpha Inhibitors in Moderate to Severe Psoriasis? March 31, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Irene Koulinska, Sc.D, M.D., is a research analyst at Decision Resources. Dr. Koulinska has more than ten years’ experience in scientific research and has coauthored 11 peer-reviewed articles. She has served as a reviewer for the Thrasher Research Fund (USA), the Wellcome Trust (U.K.), the Colombian Institute for the Development of Science and Technology and the Journal of Infectious Diseases. Upon completion of her medical studies, Dr. Koulinska obtained a doctoral degree from Harvard School of Public Health, where she investigated the mechanism of mother-to-child transmission of HIV and the establishment of viral reservoirs.